SWOG clinical trial number
E8897
Correlation of Histopathology, Immunohistochemistry and Quantitative Radiology with Outcome in Early Stage Nonseminomatous Germ Cell Tumor
Closed
Phase
Research committees
Genitourinary Cancer
Treatment
Surgery
Eligibility Criteria Expand/Collapse
Pts must have clinical Stage A nonseminomatous germ cell tumor of the testis. AFP and HCG must be normal or falling after orchiectomy at a rate consistent w/known half lives. Pt must have no evidence of mets on PE, chest x-ray, or abd/pelvic CT w/in 4 wks from reg. Pts must have had radical inguinal orchiectomy or simultaneous orchiectomy and RPLND w/in 12 wks prior to reg. Pt must have no hx of malignancy including prior testis primary. Pt must have pure seminoma (unless assoc w/elev AFP at dx). Pts must not be managed w/primary chemo. Pts must be >/= 15 years.
Other Clinical Trials
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase